APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Therapy On Cardiovascular Disease

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Selected research

Market Outlook & Growth Opportunities

Global Gene Therapy On Cardiovascular Disease Market Outlook and Growth Opportunities 2026

29 December 2025195 pages

Choose your research edition.

Industry ResearchGene Therapy On Cardiovascular Disease Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Therapy On Cardiovascular Disease Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Gene Therapy On Cardiovascular Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Therapy On Cardiovascular Disease Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Therapy On Cardiovascular Disease Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.

Read the full market overview

This report provides an overview of the global Gene Therapy On Cardiovascular Disease market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gene Therapy On Cardiovascular Disease and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gene Therapy On Cardiovascular Disease revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gene Therapy On Cardiovascular Disease market.

Gene Therapy On Cardiovascular Disease Segment by Company

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

bluebird bio

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Gene Therapy On Cardiovascular Disease Segment by Type

Viral Gene Therapy

Non-Viral Gene Therapy

Gene Therapy On Cardiovascular Disease Segment by Application

Heart Disease

Vascular Disease

Gene Therapy On Cardiovascular Disease Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gene Therapy On Cardiovascular Disease status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gene Therapy On Cardiovascular Disease key companies, revenue, market share, and recent developments.

3. To split the Gene Therapy On Cardiovascular Disease breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gene Therapy On Cardiovascular Disease market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gene Therapy On Cardiovascular Disease significant trends, drivers, influence factors in global and regions.

6. To analyze Gene Therapy On Cardiovascular Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy On Cardiovascular Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy On Cardiovascular Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy On Cardiovascular Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Therapy On Cardiovascular Disease industry.

Chapter 3: Detailed analysis of Gene Therapy On Cardiovascular Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gene Therapy On Cardiovascular Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gene Therapy On Cardiovascular Disease in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gene Therapy On Cardiovascular Disease Industry Trends Table 2. Gene Therapy On Cardiovascular Disease Industry Drivers Table 3. Gene Therapy On Cardiovascular Disease Industry Opportunities and Challenges Table 4. Gene Therapy On Cardiovascular Disease Industry Restraints Table 5. Global Gene Therapy On Cardiovascular Disease Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gene Therapy On Cardiovascular Disease Revenue Share by Company (2021-2026) Table 7. Global Gene Therapy On Cardiovascular Disease Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gene Therapy On Cardiovascular Disease Key Company Manufacturing Base & Headquarters Table 9. Global Gene Therapy On Cardiovascular Disease Company, Product Type & Application Table 10. Global Gene Therapy On Cardiovascular Disease Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gene Therapy On Cardiovascular Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Viral Gene Therapy Table 15. Significant Companies of Non-Viral Gene Therapy Table 16. Global Gene Therapy On Cardiovascular Disease Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gene Therapy On Cardiovascular Disease Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Gene Therapy On Cardiovascular Disease Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Gene Therapy On Cardiovascular Disease Sales Value Share by Type (2021-2026) Table 20. Global Gene Therapy On Cardiovascular Disease Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Heart Disease Table 22. Significant Companies of Vascular Disease Table 23. Global Gene Therapy On Cardiovascular Disease Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Gene Therapy On Cardiovascular Disease Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Gene Therapy On Cardiovascular Disease Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Gene Therapy On Cardiovascular Disease Sales Value Share by Application (2021-2026) Table 27. Global Gene Therapy On Cardiovascular Disease Sales Value Share by Application (2027-2032) Table 28. Global Gene Therapy On Cardiovascular Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Gene Therapy On Cardiovascular Disease Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Gene Therapy On Cardiovascular Disease Sales Value Share by Region (2021-2026) Table 31. Global Gene Therapy On Cardiovascular Disease Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Gene Therapy On Cardiovascular Disease Sales Value Share by Region (2027-2032) Table 33. Global Gene Therapy On Cardiovascular Disease Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Gene Therapy On Cardiovascular Disease Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Gene Therapy On Cardiovascular Disease Sales Value Market Share by Country (2021-2026) Table 36. Global Gene Therapy On Cardiovascular Disease Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Gene Therapy On Cardiovascular Disease Sales Value Market Share by Country (2027-2032) Table 38. Biogen Company Information Table 39. Biogen Business Overview Table 40. Biogen Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Biogen Gene Therapy On Cardiovascular Disease Product Portfolio Table 42. Biogen Recent Development Table 43. Novartis Company Information Table 44. Novartis Business Overview Table 45. Novartis Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Novartis Gene Therapy On Cardiovascular Disease Product Portfolio Table 47. Novartis Recent Development Table 48. Gilead Sciences Company Information Table 49. Gilead Sciences Business Overview Table 50. Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio Table 52. Gilead Sciences Recent Development Table 53. Sarepta Therapeutics Company Information Table 54. Sarepta Therapeutics Business Overview Table 55. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio Table 57. Sarepta Therapeutics Recent Development Table 58. Alnylam Pharmaceuticals Company Information Table 59. Alnylam Pharmaceuticals Business Overview Table 60. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio Table 62. Alnylam Pharmaceuticals Recent Development Table 63. Amgen Company Information Table 64. Amgen Business Overview Table 65. Amgen Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Amgen Gene Therapy On Cardiovascular Disease Product Portfolio Table 67. Amgen Recent Development Table 68. Spark Therapeutics Company Information Table 69. Spark Therapeutics Business Overview Table 70. Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio Table 72. Spark Therapeutics Recent Development Table 73. Akcea Therapeutics Company Information Table 74. Akcea Therapeutics Business Overview Table 75. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio Table 77. Akcea Therapeutics Recent Development Table 78. bluebird bio Company Information Table 79. bluebird bio Business Overview Table 80. bluebird bio Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio Table 82. bluebird bio Recent Development Table 83. Sunway Biotech Company Information Table 84. Sunway Biotech Business Overview Table 85. Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio Table 87. Sunway Biotech Recent Development Table 88. SIBIONO Company Information Table 89. SIBIONO Business Overview Table 90. SIBIONO Gene Therapy On Cardiovascular Disease Sales (Kiloton), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 91. SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio Table 92. SIBIONO Recent Development Table 93. AnGes Company Information Table 94. AnGes Business Overview Table 95. AnGes Gene Therapy On Cardiovascular Disease Sales (Kiloton), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 96. AnGes Gene Therapy On Cardiovascular Disease Product Portfolio Table 97. AnGes Recent Development Table 98. Orchard Therapeutics Company Information Table 99. Orchard Therapeutics Business Overview Table 100. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Sales (Kiloton), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 101. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio Table 102. Orchard Therapeutics Recent Development Table 103. Human Stem Cells Institute Company Information Table 104. Human Stem Cells Institute Business Overview Table 105. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Sales (Kiloton), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 106. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio Table 107. Human Stem Cells Institute Recent Development Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Gene Therapy On Cardiovascular Disease Product Image Figure 2. Global Gene Therapy On Cardiovascular Disease Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Therapy On Cardiovascular Disease Market Size (2021-2032) & (US$ Million) Figure 4. Global Gene Therapy On Cardiovascular Disease Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Viral Gene Therapy Image Figure 8. Non-Viral Gene Therapy Image Figure 9. Global Gene Therapy On Cardiovascular Disease Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Gene Therapy On Cardiovascular Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Gene Therapy On Cardiovascular Disease Sales Value Share by Type (2021-2032) Figure 12. Heart Disease Image Figure 13. Vascular Disease Image Figure 14. Global Gene Therapy On Cardiovascular Disease Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Gene Therapy On Cardiovascular Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Gene Therapy On Cardiovascular Disease Sales Value Share by Application (2021-2032) Figure 17. Global Gene Therapy On Cardiovascular Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Gene Therapy On Cardiovascular Disease Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Gene Therapy On Cardiovascular Disease Sales Value (2021-2032) & (US$ Million) Figure 20. North America Gene Therapy On Cardiovascular Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Gene Therapy On Cardiovascular Disease Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Gene Therapy On Cardiovascular Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Gene Therapy On Cardiovascular Disease Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Gene Therapy On Cardiovascular Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Gene Therapy On Cardiovascular Disease Sales Value (2021-2032) & (US$ Million) Figure 26. South America Gene Therapy On Cardiovascular Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Gene Therapy On Cardiovascular Disease Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Gene Therapy On Cardiovascular Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Therapy
  • Non-Viral Gene Therapy
Applications
  • Heart Disease
  • Vascular Disease
Companies covered
  • Biogen
  • Novartis
  • Gilead Sciences
  • Sarepta Therapeutics
  • Alnylam Pharmaceuticals
  • Amgen
  • Spark Therapeutics
  • Akcea Therapeutics
  • bluebird bio
  • Sunway Biotech
  • SIBIONO
  • AnGes
  • Orchard Therapeutics
  • Human Stem Cells Institute

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gene Therapy On Cardiovascular Disease Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gene Therapy On Cardiovascular Disease Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gene Therapy On Cardiovascular Disease Market Dynamics
  1. 2.1 Gene Therapy On Cardiovascular Disease Industry Trends
  2. 2.2 Gene Therapy On Cardiovascular Disease Industry Drivers
  3. 2.3 Gene Therapy On Cardiovascular Disease Industry Opportunities and Challenges
  4. 2.4 Gene Therapy On Cardiovascular Disease Industry Restraints
3 Gene Therapy On Cardiovascular Disease Market by Company
  1. 3.1 Global Gene Therapy On Cardiovascular Disease Company Revenue Ranking in 2025
  2. 3.2 Global Gene Therapy On Cardiovascular Disease Revenue by Company (2021-2026)
  3. 3.3 Global Gene Therapy On Cardiovascular Disease Company Ranking (2024-2026)
  4. 3.4 Global Gene Therapy On Cardiovascular Disease Company Manufacturing Base and Headquarters
  5. 3.5 Global Gene Therapy On Cardiovascular Disease Company Product Type and Application
  6. 3.6 Global Gene Therapy On Cardiovascular Disease Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gene Therapy On Cardiovascular Disease Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gene Therapy On Cardiovascular Disease Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gene Therapy On Cardiovascular Disease Market by Type
  1. 4.1 Gene Therapy On Cardiovascular Disease Type Introduction
  2. 4.1.1 Viral Gene Therapy
  3. 4.1.2 Non-Viral Gene Therapy
  4. 4.2 Global Gene Therapy On Cardiovascular Disease Sales Value by Type
  5. 4.2.1 Global Gene Therapy On Cardiovascular Disease Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gene Therapy On Cardiovascular Disease Sales Value by Type (2021-2032)
  7. 4.2.3 Global Gene Therapy On Cardiovascular Disease Sales Value Share by Type (2021-2032)
5 Gene Therapy On Cardiovascular Disease Market by Application
  1. 5.1 Gene Therapy On Cardiovascular Disease Application Introduction
  2. 5.1.1 Heart Disease
  3. 5.1.2 Vascular Disease
  4. 5.2 Global Gene Therapy On Cardiovascular Disease Sales Value by Application
  5. 5.2.1 Global Gene Therapy On Cardiovascular Disease Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Gene Therapy On Cardiovascular Disease Sales Value by Application (2021-2032)
  7. 5.2.3 Global Gene Therapy On Cardiovascular Disease Sales Value Share by Application (2021-2032)
6 Gene Therapy On Cardiovascular Disease Regional Value Analysis
  1. 6.1 Global Gene Therapy On Cardiovascular Disease Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gene Therapy On Cardiovascular Disease Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gene Therapy On Cardiovascular Disease Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gene Therapy On Cardiovascular Disease Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gene Therapy On Cardiovascular Disease Sales Value (2021-2032)
  7. 6.3.2 North America Gene Therapy On Cardiovascular Disease Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gene Therapy On Cardiovascular Disease Sales Value (2021-2032)
  10. 6.4.2 Europe Gene Therapy On Cardiovascular Disease Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gene Therapy On Cardiovascular Disease Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gene Therapy On Cardiovascular Disease Sales Value (2021-2032)
  16. 6.6.2 South America Gene Therapy On Cardiovascular Disease Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gene Therapy On Cardiovascular Disease Sales Value Share by Country, 2025 VS 2032
7 Gene Therapy On Cardiovascular Disease Country-level Value Analysis
  1. 7.1 Global Gene Therapy On Cardiovascular Disease Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gene Therapy On Cardiovascular Disease Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gene Therapy On Cardiovascular Disease Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gene Therapy On Cardiovascular Disease Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gene Therapy On Cardiovascular Disease Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gene Therapy On Cardiovascular Disease Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gene Therapy On Cardiovascular Disease Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Gene Therapy On Cardiovascular Disease Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Gene Therapy On Cardiovascular Disease Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Gilead Sciences
  14. 8.3.1 Gilead Sciences Company Information
  15. 8.3.2 Gilead Sciences Business Overview
  16. 8.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio
  18. 8.3.5 Gilead Sciences Recent Developments
  19. 8.4 Sarepta Therapeutics
  20. 8.4.1 Sarepta Therapeutics Company Information
  21. 8.4.2 Sarepta Therapeutics Business Overview
  22. 8.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
  24. 8.4.5 Sarepta Therapeutics Recent Developments
  25. 8.5 Alnylam Pharmaceuticals
  26. 8.5.1 Alnylam Pharmaceuticals Company Information
  27. 8.5.2 Alnylam Pharmaceuticals Business Overview
  28. 8.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio
  30. 8.5.5 Alnylam Pharmaceuticals Recent Developments
  31. 8.6 Amgen
  32. 8.6.1 Amgen Company Information
  33. 8.6.2 Amgen Business Overview
  34. 8.6.3 Amgen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Amgen Gene Therapy On Cardiovascular Disease Product Portfolio
  36. 8.6.5 Amgen Recent Developments
  37. 8.7 Spark Therapeutics
  38. 8.7.1 Spark Therapeutics Company Information
  39. 8.7.2 Spark Therapeutics Business Overview
  40. 8.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
  42. 8.7.5 Spark Therapeutics Recent Developments
  43. 8.8 Akcea Therapeutics
  44. 8.8.1 Akcea Therapeutics Company Information
  45. 8.8.2 Akcea Therapeutics Business Overview
  46. 8.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
  48. 8.8.5 Akcea Therapeutics Recent Developments
  49. 8.9 bluebird bio
  50. 8.9.1 bluebird bio Company Information
  51. 8.9.2 bluebird bio Business Overview
  52. 8.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  53. 8.9.4 bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio
  54. 8.9.5 bluebird bio Recent Developments
  55. 8.10 Sunway Biotech
  56. 8.10.1 Sunway Biotech Company Information
  57. 8.10.2 Sunway Biotech Business Overview
  58. 8.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio
  60. 8.10.5 Sunway Biotech Recent Developments
  61. 8.11 SIBIONO
  62. 8.11.1 SIBIONO Company Information
  63. 8.11.2 SIBIONO Business Overview
  64. 8.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  65. 8.11.4 SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio
  66. 8.11.5 SIBIONO Recent Developments
  67. 8.12 AnGes
  68. 8.12.1 AnGes Company Information
  69. 8.12.2 AnGes Business Overview
  70. 8.12.3 AnGes Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AnGes Gene Therapy On Cardiovascular Disease Product Portfolio
  72. 8.12.5 AnGes Recent Developments
  73. 8.13 Orchard Therapeutics
  74. 8.13.1 Orchard Therapeutics Company Information
  75. 8.13.2 Orchard Therapeutics Business Overview
  76. 8.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
  78. 8.13.5 Orchard Therapeutics Recent Developments
  79. 8.14 Human Stem Cells Institute
  80. 8.14.1 Human Stem Cells Institute Company Information
  81. 8.14.2 Human Stem Cells Institute Business Overview
  82. 8.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio
  84. 8.14.5 Human Stem Cells Institute Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst